ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

The Trajectory of Donor-Derived Cell-Free DNA (dd-cfDNA) Complements the Baseline Measurements in Heart Transplant Surveillance for Rejection

P. Shah1, R. Cheng2, H. Eisen3, B. D. Lowes4, L. Lourenco Jenkins5, Y. Fu5, K. Qu5, J. Teuteberg6, E. DePasquale7

1Inova Heart and Vascular Institute, Falls Church, VA, 2University of Washington Heart Institute, Seattle, WA, 3Pennsylvania State University, Hershey, PA, 4University of Nebraska Medical Center, Omaha, NE, 5CareDx, Brisbane, CA, 6Stanford University, Stanford, CA, 7University of Southern California, Los Angeles, CA

Meeting: 2022 American Transplant Congress

Abstract number: 235

Keywords: Heart transplant patients, Monitoring, Multicenter studies, Rejection

Topic: Clinical Science » Heart » 63 - Heart and VADs: All Topics

Session Information

Session Name: Heart and VADs: All Topics II

Session Type: Rapid Fire Oral Abstract

Date: Monday, June 6, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 3:40pm-3:50pm

Location: Hynes Room 210

*Purpose: Changes in dd-cfDNA levels over time may identify patients with evolving alloimmune injury, providing complementary information to the donor fraction. We explored the dd-cfDNA trajectories preceding biopsy-proven rejection events among single-organ heart transplant recipients enrolled in the Surveillance HeartCare® Outcomes Registry (SHORE) and undergoing longitudinal surveillance with dd-cfDNA.

*Methods: In the primary analysis, we identified patients with first-time rejection events and at least 3 preceding dd-cfDNA results, including at least one within 30 days of the index biopsy; we then selected the lowest of two earlier measurements to define the patient-specific baseline. Changes between the baseline and index dd-cfDNA result were characterized.

*Results: A total of 25 patients with biopsy-proven rejection met criteria for the initial analysis; among these, median baseline dd-cfDNA was 0.024% (IQR:-0.011% – 0.051%) and median dd-cfDNA at the time of rejection was 0.19% (IQR: 0.054%- 0.590%), representing a 7-fold (IQR 1.5-28.9) increase over a median of 57 (IQR: 42 – 69) days. Further analysis of the longitudinal AlloSure results in these patients demonstrated the dd-cfDNA began to rise about 2 months prior to the rejection episode [Figure 1].

*Conclusions: Longitudinal surveillance with dd-cfDNA allows the integration of changes over time to the individual measurements, allowing earlier identification of evolving allograft injury. Significant changes from an established baseline and between sequential values as much as 2 months prior to biopsy-proven rejection highlight how longitudinal surveillance may improve diagnostic performance.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Shah P, Cheng R, Eisen H, Lowes BD, Jenkins LLourenco, Fu Y, Qu K, Teuteberg J, DePasquale E. The Trajectory of Donor-Derived Cell-Free DNA (dd-cfDNA) Complements the Baseline Measurements in Heart Transplant Surveillance for Rejection [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/the-trajectory-of-donor-derived-cell-free-dna-dd-cfdna-complements-the-baseline-measurements-in-heart-transplant-surveillance-for-rejection/. Accessed May 28, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences